Cohort · P2-CRC-D0918Active studySynthetic mock data
ctDNA MRD-positive sub-cohort
Owner ML · last updated 2026-04-26
Size
64
Status
expanding
Inclusion criteria
2
Exclusion criteria
2
Definition
Inclusion
- +Stage III CRC s/p curative resection
- +Detectable ctDNA at week 4 post-op
Exclusion
- −Prior CRC malignancy
- −Inadequate surgical margin
expandingP2-CRC-D0918Owner MLLast updated 2026-04-26
Enrollment over time
From wk 0 (n=0) to wk 20 (n=64)
Subjects in cohort (10)
| Subject | MRN | Age / Sex | Site | Enrolled | Status |
|---|---|---|---|---|---|
| CRC-MRDP-001 Maria Alvarez | MRN 6025300 | 48 / F | Site 03 — Chicago | 2025-09-15 | withdrawn |
| CRC-MRDP-002 Henry Müller | MRN 6025301 | 51 / M | Site 09 — Munich | 2025-09-20 | active |
| CRC-MRDP-003 Rachel Sørensen | MRN 6025302 | 54 / F | Site 12 — Singapore | 2025-09-25 | active |
| CRC-MRDP-004 Robert Adebayo | MRN 6025303 | 57 / M | Site 14 — Boston | 2025-09-30 | active |
| CRC-MRDP-005 Priya Iversen | MRN 6025304 | 60 / F | Site 18 — Toronto | 2025-10-05 | active |
| CRC-MRDP-006 Theo O'Connor | MRN 6025305 | 63 / M | Site 22 — Madrid | 2025-10-10 | active |
| CRC-MRDP-007 Sara Tanaka | MRN 6025306 | 66 / F | Site 03 — Chicago | 2025-10-15 | active |
| CRC-MRDP-008 Antonio Marquez | MRN 6025307 | 69 / M | Site 09 — Munich | 2025-10-20 | active |
| CRC-MRDP-009 Aisha Hassan | MRN 6025308 | 72 / F | Site 12 — Singapore | 2025-10-25 | active |
| CRC-MRDP-010 Omar Singh | MRN 6025309 | 75 / M | Site 14 — Boston | 2025-10-30 | active |
Linked study
P2-CRC-D0918
ctDNA-guided adjuvant de-escalation
Recurrence-free survival, 24 mo · 87/160 enrolled
Sister cohorts in P2-CRC-D0918
Endpoints attached to this protocol
Cross-links